BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38564259)

  • 41. The emerging era of personalized medicine in advanced colorectal cancer.
    Wu CWK; Reid M; Leedham S; Lui RN
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1411-1425. PubMed ID: 35815339
    [TBL] [Abstract][Full Text] [Related]  

  • 42. State-of-the-Art Management of Colorectal Cancer: Treatment Advances and Innovation.
    Pathak PS; Chan G; Deming DA; Chee CE
    Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e438466. PubMed ID: 38768405
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype.
    Deng J; Tian AL; Pan H; Sauvat A; Leduc M; Liu P; Zhao L; Zhang S; Chen H; Taly V; Laurent-Puig P; Senovilla L; Li Y; Kroemer G; Kepp O
    Cell Death Dis; 2021 Oct; 12(11):978. PubMed ID: 34675191
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical importance of DNA repair in sporadic colorectal cancer.
    Laporte GA; Leguisamo NM; Kalil AN; Saffi J
    Crit Rev Oncol Hematol; 2018 Jun; 126():168-185. PubMed ID: 29759559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
    Dreyer C; Afchain P; Trouilloud I; André T
    Bull Cancer; 2016; 103(7-8):643-50. PubMed ID: 27345450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The potential role of platelets in the consensus molecular subtypes of colorectal cancer.
    Lam M; Roszik J; Kanikarla-Marie P; Davis JS; Morris J; Kopetz S; Menter DG
    Cancer Metastasis Rev; 2017 Jun; 36(2):273-288. PubMed ID: 28681242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Back to the Colorectal Cancer Consensus Molecular Subtype Future.
    Menter DG; Davis JS; Broom BM; Overman MJ; Morris J; Kopetz S
    Curr Gastroenterol Rep; 2019 Jan; 21(2):5. PubMed ID: 30701321
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.
    Fessler E; Jansen M; De Sousa E Melo F; Zhao L; Prasetyanti PR; Rodermond H; Kandimalla R; Linnekamp JF; Franitza M; van Hooff SR; de Jong JH; Oppeneer SC; van Noesel CJ; Dekker E; Stassi G; Wang X; Medema JP; Vermeulen L
    Oncogene; 2016 Nov; 35(46):6026-6037. PubMed ID: 27157610
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
    Lin PS; Semrad TJ
    Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Consensus molecular subtyping improves the clinical usefulness of canonical tumor markers for colorectal cancer.
    Kagawa H; Hatakeyama K; Shiomi A; Hino H; Manabe S; Yamaoka Y; Nagashima T; Ohshima K; Urakami K; Yamaguchi K
    Biomed Res; 2022; 43(6):201-209. PubMed ID: 36517022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A third Notch in colorectal cancer progression and metastasis.
    Koch U; Radtke F
    J Exp Med; 2020 Oct; 217(10):. PubMed ID: 32852523
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic value of the PrP
    Ghazi A; Le Corre D; Pilati C; Taieb J; Aparicio T; Didelot A; Dedhar S; Mulot C; Le Malicot K; Djouadi F; de Reynies A; Launay JM; Laurent-Puig P; Mouillet-Richard S
    Oncoimmunology; 2021; 10(1):1940674. PubMed ID: 34249475
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
    Linnekamp JF; Hooff SRV; Prasetyanti PR; Kandimalla R; Buikhuisen JY; Fessler E; Ramesh P; Lee KAST; Bochove GGW; de Jong JH; Cameron K; Leersum RV; Rodermond HM; Franitza M; Nürnberg P; Mangiapane LR; Wang X; Clevers H; Vermeulen L; Stassi G; Medema JP
    Cell Death Differ; 2018 Mar; 25(3):616-633. PubMed ID: 29305587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches.
    Atreya CE; Yaeger R; Chu E
    Am Soc Clin Oncol Educ Book; 2017; 37():246-256. PubMed ID: 28561718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Colony-stimulating factor 3 signaling in colon and rectal cancers: Immune response and CMS classification in TCGA data.
    Saunders AS; Bender DE; Ray AL; Wu X; Morris KT
    PLoS One; 2021; 16(2):e0247233. PubMed ID: 33606788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and molecular characterization of early-onset colorectal cancer.
    Willauer AN; Liu Y; Pereira AAL; Lam M; Morris JS; Raghav KPS; Morris VK; Menter D; Broaddus R; Meric-Bernstam F; Hayes-Jordan A; Huh W; Overman MJ; Kopetz S; Loree JM
    Cancer; 2019 Jun; 125(12):2002-2010. PubMed ID: 30854646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current and evolving biomarkers for precision oncology in the management of metastatic colorectal cancer.
    Henry JT; Johnson B
    Chin Clin Oncol; 2019 Oct; 8(5):49. PubMed ID: 31500426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.